

Universal Biosensors, Inc.
ARBN 121 559 993

1 Corporate Avenue
Rowville Victoria 3178
Australia

Telephone +61 3 9213 9000
Facsimile +61 3 9213 9099
Email info@universalbiosensors.com
www.universalbiosensors.com



11 November 2021

UBI signs Master Collaboration Agreement with Mayo Clinic

Universal Biosensors, Inc. (ASX:UBI) advises that it has entered into a Master Collaboration Agreement (MCA) with Mayo Clinic Biopharma Diagnostics (Mayo Clinic), one of the world's most prestigious oncology research and treatment institutions based in Rochester Minnesota USA.

The MCA covers multiple potential projects including work on UBI's Tn antigen cancer biosensor.

End

Enquiries:
John Sharman
Chief Executive Officer
+61 (0) 414 440 680

Announcement authorised by the Board of Directors of Universal Biosensors, Inc.



About Universal Biosensors

Universal Biosensors, founded in 2001, specialises in the design and development of electrochemical cells (strips) used in conjunction with point of use devices that are used in various industries such as healthcare (point of care), wine, food, and agriculture. Our wine testing platform Sentia is UBI's newest product which is being launched globally. For additional information regarding Universal Biosensors, Inc., refer to: <http://www.universalbiosensors.com>.

About Mayo Clinic

The Mayo Clinic is a nonprofit American academic medical center focused on integrated health care, education, and research. Mayo Clinic is one of the largest not-for-profit, academic health systems in the U.S., with USD \$14 billion in annual revenues and 65,000 employees. With a focus on caring for patients with serious, complex illnesses, Mayo Clinic operates in five states and cares for more than one million people a year, from all 50 states and nearly 140 countries. Mayo has recently been announced the #1 in the 2021-2022 "Best Hospitals" rankings in the nation by U.S. News and World Report.

Forward-Looking Statements

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the US Securities Exchange Act of 1934. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposals outlined in this release will occur, and the terms of any such proposal are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.